Data gathered: April 15
AI Stock Analysis - Axsome Therapeutics (AXSM)
Analysis generated March 20, 2025. Powered by Chat GPT.
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing novel therapies for the treatment of central nervous system (CNS) disorders. The company's pipeline includes products designed to address conditions such as depression, migraines, and other neurological and psychiatric ailments. With a strong emphasis on innovation and addressing significant unmet medical needs, Axsome has positioned itself as a key player in the CNS therapeutic market.
Stock Alerts - Axsome Therapeutics (AXSM)
 |
Axsome Therapeutics | April 10 Price is down by -5.1% in the last 24h. |
|
Axsome Therapeutics | April 9 Price is down by -5.9% in the last 24h. |
|
Axsome Therapeutics | April 4 Price is down by -5.6% in the last 24h. |
|
Axsome Therapeutics | April 1 Price is down by -5.5% in the last 24h. |
Alternative Data for Axsome Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 82 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 49,000 | Sign up | Sign up | Sign up |
| Employee Rating | 64 | Sign up | Sign up | Sign up |
| Google Trends | 19 | Sign up | Sign up | Sign up |
| Patents | 243 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 74 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 11,713 | Sign up | Sign up | Sign up |
| Twitter Followers | 503 | Sign up | Sign up | Sign up |
| Twitter Mentions | 22 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 68 | Sign up | Sign up | Sign up |
| Linkedin Employees | 703 | Sign up | Sign up | Sign up |
About Axsome Therapeutics
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.
| Price | $103.53 |
| Target Price | Sign up |
| Volume | 767,800 |
| Market Cap | $4.78B |
| Year Range | $80.05 - $137.75 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Earnings Date | May 5 '25 |
| Industry | Biotechnology |
In the news
SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO DISMISS: Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); and Virtu Financial Inc. (NASDAQ: VIRT) Should Contact Grabar Law Office TodayApril 14 - GlobeNewswire |
|
Attention Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra Lifesciences Holdings Corporation (NASDAQ: IART); and Virtu Financial Inc. (NASDAQ: VIRT): Grabar Law Office Investigates Claims on Your BehalfApril 11 - GlobeNewswire |
|
 |
Zacks Research Analysts Increase Earnings Estimates for AXSMApril 10 - ETF Daily News |
|
Zacks Research Issues Negative Estimate for AXSM EarningsApril 9 - ETF Daily News |
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the FirmApril 9 - GlobeNewswire |
|
AAN 2025: Axsome Therapeutics’ treatment for Alzheimer’s agitation shows promiseApril 9 - Yahoo Entertainment |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 119M | 11M | 108M | -75M | -71M | -1.540 |
| Q3 '24 | 105M | 8.4M | 96M | -65M | -61M | -1.342 |
| Q2 '24 | 87M | 8.1M | 79M | -79M | -78M | -1.670 |
| Q1 '24 | 75M | 8.1M | 67M | -68M | -65M | -1.440 |
| Q4 '23 | 72M | 7.4M | 64M | -99M | -97M | -2.080 |
Insider Transactions View All
| Pizzie Nick filed to sell 42,187 shares at $131.1. February 14 '25 |
| Pizzie Nick filed to sell 42,187 shares at $129.9. February 14 '25 |
| Saad Mark E filed to sell 10,002 shares at $91.3. September 11 '24 |
| Jacobson Mark L. filed to sell 5,783 shares at $84.3. August 9 '24 |
| Coleman Mark filed to sell 14,600 shares at $75.1. May 29 '24 |
Similar companies
Read more about Axsome Therapeutics (AXSM) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Axsome Therapeutics?
The Market Cap of Axsome Therapeutics is $4.78B.
When does Axsome Therapeutics report earnings?
Axsome Therapeutics will report its next earnings on May 5 '25.
What is the current stock price of Axsome Therapeutics?
Currently, the price of one share of Axsome Therapeutics stock is $103.53.
How can I analyze the AXSM stock price chart for investment decisions?
The AXSM stock price chart above provides a comprehensive visual representation of Axsome Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Axsome Therapeutics shares. Our platform offers an up-to-date AXSM stock price chart, along with technical data analysis and alternative data insights.
Does AXSM offer dividends to its shareholders?
As of our latest update, Axsome Therapeutics (AXSM) does not offer dividends to its shareholders. Investors interested in Axsome Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Axsome Therapeutics?
Some of the similar stocks of Axsome Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.